daraxonrasib   Click here for help

GtoPdb Ligand ID: 13368

Synonyms: RAS Inhibitor A122 | Rasonque® | RMC-6236 | RMC6236
Approved drug
daraxonrasib is an approved drug
Compound class: Synthetic organic
Comment: RMC-6236 is a macrocyclic, noncovalent (reversible) pan-RAS inhibitor [1-2]. It was developed using structure-guided design from the bacterial polyketide Sanglifehrin A. RMC-6236 forms a binary complex with the ubiquitously-expressed chaperone protein cyclophilin A. The binary complex has high affinity for RAS proteins, and interactions lead to the formation of an inhibitory tri-complex [4]. RMC-6236 has activity against active state (GTP-bound) mutant and wild-type RAS proteins. This mode of action is described as RAS(ON) inhibition, and is intended to target tumours with oncogenic RAS mutations beyond the common driver mutation KRASG12C [2]. The chemical structure of RMC-6236 is identical to that for the INN daraxonrasib (proposed list 132, Feb. 2025).
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 13
Hydrogen bond donors 2
Rotatable bonds 8
Topological polar surface area 156.71
Molecular weight 811.05
XLogP 5.08
No. Lipinski's rules broken 3

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)

SMILES / InChI / InChIKey
Click here for help
Canonical SMILES CCN1C2=C3C=C(C=C2)C4=CSC(=N4)C[C@@H](C(=O)N5CCC[C@@H](C(=O)OCC(C)(C)CC3=C1C6=C([C@H](C)OC)N=CC(=C6)N7CCN(C)CC7)N5)NC(=O)[C@H]8C[C@@H]8C
Isomeric SMILES CCN1C2=C3C=C(C=C2)C4=CSC(=N4)C[C@@H](C(=O)N5CCC[C@H](N5)C(=O)OCC(CC3=C1C6=C(N=CC(=C6)N7CCN(CC7)C)[C@H](C)OC)(C)C)NC(=O)[C@H]8C[C@@H]8C
InChI InChI=1S/C44H58N8O5S/c1-8-51-37-12-11-28-19-31(37)33(40(51)32-20-29(23-45-39(32)27(3)56-7)50-16-14-49(6)15-17-50)22-44(4,5)25-57-43(55)34-10-9-13-52(48-34)42(54)35(21-38-46-36(28)24-58-38)47-41(53)30-18-26(30)2/h11-12,19-20,23-24,26-27,30,34-35,48H,8-10,13-18,21-22,25H2,1-7H3,(H,47,53)/t26-,27-,30-,34-,35-/m0/s1
InChI Key FVICRBSEYSHKFY-JYQNNKODSA-N

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)

No information available.
Summary of Clinical Use Click here for help
Daraxonrasib (RMC-6236) was progressed to clinical evaluation to determine safety and efficacy in patients with KRAS-mutant solid tumours. Phase 3 results from a study comparing daraxonrasib with chemotherapy in patients with previously treated metastatic pancreatic cancer were published in spring 2026 [3]. First approval was granted by the US FDA in August 2026, to treat previously treated metastatic pancreatic adenocarcinoma.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT05379985 Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS Phase 1 Interventional Revolution Medicines, Inc. 5
NCT06881784 Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301) Phase 3 Interventional Revolution Medicines, Inc.
NCT07252232 Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC) Phase 3 Interventional Revolution Medicines, Inc.
NCT06625320 Phase 3 Study of Daraxonrasib (RMC-6236) in Patients With Previously Treated Metastatic Pancreatic Ductal Adenocarcinoma (PDAC) Phase 3 Interventional Revolution Medicines, Inc. In this study daraxonrasib treatment led to significantly longer overall survival and progression-free survival than chemotherapy, in patients with previously treated, metastatic pancreatic ductal adenocarcinoma (mPDAC). 3